NCT05003453View on ClinicalTrials.gov

The Effectiveness of a Topical Palmitoylethanolamide (PEA) Formulation (Levagen+) for Reducing Symptoms of Eczema

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

November 29, 2021

Primary Completion Date

June 3, 2022

Study Completion Date

June 30, 2022

Conditions
Eczema, Atopic
Interventions
DRUG

1.5% Palmitoylethanolamide (PEA) sold as Levagen+

A topical cream containing 1.5% PEA applied to the affected site 2-times daily, liberally to coat and cover affected area.

DRUG

Placebo Comparator

A comparator placebo topical moisturiser cream (an unscented moisturising base cream) applied to the affected site 2 times daily, liberally to coat and cover affected area.

Trial Locations (1)

4006

RDC Global Pty Ltd, Brisbane

All Listed Sponsors
lead

RDC Clinical Pty Ltd

INDUSTRY

NCT05003453 - The Effectiveness of a Topical Palmitoylethanolamide (PEA) Formulation (Levagen+) for Reducing Symptoms of Eczema | Biotech Hunter | Biotech Hunter